Relmada Therapeutics Inc (RLMD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.11 (-2.14%), Market cap $0.72B, 52-week low–high $0.51 ~ $7.86.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquarter
Financial statements, price targets, institutional (13F) holdings and related news for Relmada Therapeutics Inc are updated in real time on BlackAll Trade.
Relmada Therapeutics Inc trades at $4.11 (-2.14%). Real-time quotes and charts are available on BlackAll Trade.
Relmada Therapeutics Inc has a market cap of about $0.72B.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of g